Researchers at UNMC are studying a new drug that may assist people with mild-to-moderate Alzheimer’s disease.
Dr. Daniel Murman, professor in the UNMC Department of Neurological Sciences, is the lead investigator on the clinical trial.
Murman says the purpose of the drug would be to slow the progression of the disease. He says the new drug is not expected to be a cure or dramatically reverse the changes that have already happened.
"The drug has properties that help protect nerve cells that are going through this process of degeneration that have Alzheimer's Disease. It also has some properties that help nerve cells reconnect. As part of the Alzheimer's process, nerve cells disconnect from each other so they can't communicate with each other. Then some of the nerve cells degenerate and die. So the drug is trying to stop that process to a degree."
Murman says UNMC is looking for individuals for this study. Eligible participants will be between 55 and 85 years of age, have a diagnosis of mild-to-moderate Alzheimer’s disease and have been taking either Aricept or using the Exelon patch for at least six months.
He says those participating will also need to have a study partner who is able to attend visits with them. For more information, the email address is NOBLEStudy@mslgroup.com.